Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

Amendment 2 of the protocol added a new study arm (Cohort B2) for participants with advanced
head and neck cancer who will receive a lower dose of pembrolizumab (MK-3475) every three
weeks (Q3W); participants with programmed cell death ligand 1 (PD-L1)-negative tumors will
also be analyzed separately.

Inclusion Criteria:

- Histologically or cytologically-confirmed diagnosis of tumor that is recurrent,
metastatic, or persistent:

- For Cohort A - triple negative breast cancer (estrogen, progesterone, and human
epidermal growth factor receptor 2 [HER2] negative)

- For Cohort B - squamous cell carcinoma of the head and neck (including
HPV-positive head and neck squamous cell cancer).

- For Cohort C - urothelial tract cancer of the renal pelvis, ureter, bladder, or
urethra (transitional cell or non-transitional cell histology)

- For Cohort D - adenocarcinoma of the stomach or gastroesophageal junction

- For Cohort B2 - squamous cell carcinoma of the head and neck (both HPV-positive
and -negative head and neck squamous cell cancer)

- Any number of prior treatment regimens

- Measurable disease

- Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1

- Female participants of childbearing potential must be willing to use 2 methods of
birth control or be surgically sterile, or abstain from heterosexual activity for the
course of the study through 120 days after the last dose of study treatment

- Male participants must agree to use an adequate method of contraception starting with
the first dose of study therapy through 120 days after the last dose of study
treatment

Exclusion Criteria:

- Currently participating in/has participated in a study of an investigational agent or
using an investigational device within 4 weeks of the first dose of study treatment

- Diagnosis of immunosuppression or receiving systemic steroid therapy or any other
form of immunosuppressive therapy within 7 days prior to the first dose of study
treatment

- Anti-cancer monoclonal antibody treatment within 4 weeks prior to study Day 1 or not
recovered from adverse events due to agents administered more than 4 weeks earlier

- Chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks
prior to study Day 1 or not recovered from adverse events due to a previously
administered agent

- Known additional malignancy that is progressing or requires active treatment
excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or
in situ cervical cancer that has undergone potentially curative therapy

- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

- Active autoimmune disease requiring systemic treatment within the past 3 months or
documented history of clinically severe autoimmune disease, or syndrome that requires
systemic steroids or immunosuppressive agents

- Evidence of interstitial lung disease

- Active infection requiring systemic therapy

- Known psychiatric or substance abuse disorders

- Pregnant, breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of trial treatment

- Prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death
1 ligand 1(PD-L1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4) antibody

- Known history of human immunodeficiency virus (HIV)

- Known active Hepatitis B or Hepatitis C

- Received live vaccine within 30 days prior to start of study treatment